Clinical Trial Update: Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ipilimumab after regulatory T cell depletion with denileukin diftitox in stage IIIC/IV melanoma was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Denileukin diftitox (denileukin diftitox)
• ipilimumab (ipilimumab)

Snippet

Sponsor: University of Louisville | Conditions: Metastatic Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2021-10-25